Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 23;6(4):402-413.
doi: 10.1016/j.synbio.2021.11.004. eCollection 2021 Dec.

finDr: A web server for in silico D-peptide ligand identification

Affiliations

finDr: A web server for in silico D-peptide ligand identification

Helena Engel et al. Synth Syst Biotechnol. .

Abstract

In the rapidly expanding field of peptide therapeutics, the short in vivo half-life of peptides represents a considerable limitation for drug action. D-peptides, consisting entirely of the dextrorotatory enantiomers of naturally occurring levorotatory amino acids (AAs), do not suffer from these shortcomings as they are intrinsically resistant to proteolytic degradation, resulting in a favourable pharmacokinetic profile. To experimentally identify D-peptide binders to interesting therapeutic targets, so-called mirror-image phage display is typically performed, whereby the target is synthesized in D-form and L-peptide binders are screened as in conventional phage display. This technique is extremely powerful, but it requires the synthesis of the target in D-form, which is challenging for large proteins. Here we present finDr, a novel web server for the computational identification and optimization of D-peptide ligands to any protein structure (https://findr.biologie.uni-freiburg.de/). finDr performs molecular docking to virtually screen a library of helical 12-mer peptides extracted from the RCSB Protein Data Bank (PDB) for their ability to bind to the target. In a separate, heuristic approach to search the chemical space of 12-mer peptides, finDr executes a customizable evolutionary algorithm (EA) for the de novo identification or optimization of D-peptide ligands. As a proof of principle, we demonstrate the validity of our approach to predict optimal binders to the pharmacologically relevant target phenol soluble modulin alpha 3 (PSMα3), a toxin of methicillin-resistant Staphylococcus aureus (MRSA). We validate the predictions using in vitro binding assays, supporting the success of this approach. Compared to conventional methods, finDr provides a low cost and easy-to-use alternative for the identification of D-peptide ligands against protein targets of choice without size limitation. We believe finDr will facilitate D-peptide discovery with implications in biotechnology and biomedicine.

Keywords: D-AA, dextrorotatory amino acid; D-peptide; EA, evolutionary algorithm; Evolutionary algorithm; L-AA, levorotatory amino acid; MD, molecular dynamics; MIEA, mirror-image evolutionary algorithm; MIPD, mirror-image phage display; MIVS, mirror-image virtual screening; MRSA, methicillin-resistant Staphylococcus aureus; Mirror-image phage display; Molecular docking; NCL, native chemical ligation; PD-1, receptor programmed death 1; PPI, protein-protein interaction; PSMα3, phenol soluble modulin alpha 3; Peptide design; SPPS, solid phase peptide synthesis; Web server.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Fig. 1
Fig. 1
Schematic representation of the stereochemistry of a protein - peptide interaction. If an L-peptide ligand binds a protein's mirror-image (D-protein), then their corresponding mirror-images (D-peptide ligand and L-protein) will also bind to each other in exactly the same fashion.
Fig. 2
Fig. 2
Selective binding of MIPD-derived phage clones to D-PSMα3. Results of a phage ELISA performed with isolated phages from MIPD displaying the indicated peptides on their surfaces. The absorbance resulting from phage binding to D-PSMα3 coated wells was normalized to that resulting from unspecific phage binding to D-PSMα3 free control wells. As negative control, a phage clone was randomly chosen from the phage library. Data represent mean + SEM of triplicates. P values were calculated by a two sided, unpaired Student's t-test ***: P ≤ 0.0001.
Fig. 3
Fig. 3
Schematic representation of the MIPD and MIVS workflow. MIPD: A library of random L-peptides expressed on the surface of bacteriophages is selected via surface panning against a chemically synthesized D-analogue of the target L-protein. MIVS: A structural library of helical L-peptide segments extracted from the PDB is screened for binding affinity towards an in silico mirrored D-version of the target L-protein structure via molecular docking. Both methods yield L-peptide ligands to D-protein targets. Consequently, the corresponding D-peptides bind to the naturally occurring L-protein target (see Fig. 1).
Fig. 4
Fig. 4
Mirror-image virtual screening oftheL-peptide library to D-PSMα3. A: Distribution of binding energies of 28.647 L-peptides, each docked to 5 different conformations of D-PSMα3. B: Histogram of the L-peptides’ mean binding energy to the 5 different D-PSMα3 conformers.
Fig. 5
Fig. 5
Diagram of MIEA. The fitness of all peptides in a population Pn is evaluated by molecular docking. Based on this, a population Pn+1 is newly generated by copying the peptides with the lowest binding energy, with and without crossover recombination of their sequences, and introducing random mutations. Further, a number of X individual peptides with the best binding energy are directly copied into the population Pn+1 without alteration. This population Pn+1 is then again evaluated via docking to complete the MIEA cycle.
Fig. 6
Fig. 6
Improvement of binding affinity of L-peptides to D-PSMα3 over 15 generations of MIEA. A: Binding energies of L-peptides to D-PSMα3 per generation of an MIEA, assessed by molecular docking using AutoDock Vina. Only the 20 best binding peptides of each generation are shown. B: Binding energy of all 88 peptides to D-PSMα3 in each generation. Mean binding energy of each peptide population and SEM are shown. Statistical significance of the difference from the initial population was determined by an unpaired, two-tailed t-test. C: Association of the L-peptide ligand L-EA2 (sequence FKWRYERDKKQS, shown in orange) to D-PSMα3 (shown in blue). D: Association of the D-peptide ligand D-EA2 (sequence all D-FKWRYERDKKQS, shown in orange) to L-PSMα3 (shown in blue). Bound states in C and D were obtained by Autodock Vina.
Fig. 7
Fig. 7
SCORE binding assay of MIPD- and MIEA-derived peptide ligands to PSMα3. Real-time binding kinetics of L-MIPD27 and L-EA2 to D-PSMα3 as measured by SCORE. The mean intensities of four spots (EA2, MIPD27) and 2 spots (scrambled) with standard deviation are depicted. The association and dissociation phases are indicated; the dissociation kinetic starts shortly after induction of the washing step due to methodological reasons.
Fig. 8
Fig. 8
D-peptide ligand identification for ErbB2 with finDr. A: MIVS - Histogram of the binding energies of all docked library peptides, screenshot from finDr results webpage. B: MIEA - Binding energy of L-peptides to D-ErbB2 per generation of the MIEA. Only the 20 best binding peptides are shown. C: MIEA - Mean binding energy per generation D: Binding energy of the best binding peptide in each generation of MIEA. E, F: L-ErbB2 in complex with its D-peptide ligand derived from MIVS (E) and MIEA (F) (visualized by PyMOL, Gridbox for docking is shown in black).

References

    1. Angell Y., Holford M., Moos W.H. Building on success: a bright future for peptide therapeutics. Protein Pept. Lett. 2018;25:1044–1050. doi: 10.2174/0929866525666181114155542. - DOI - PubMed
    1. Al Shaer D., Al Musaimi O., Albericio F., de La Torre B.G. FDA TIDES (peptides and Oligonucleotides) harvest. Pharmaceuticals. 2019;13 doi: 10.3390/ph13030040. 2020. - DOI - PMC - PubMed
    1. Clément K., van den Akker E., Argente J., Bahm A., Chung W.K., Connors H., de Waele K., Farooqi I.S., Gonneau-Lejeune J., Gordon G., Kohlsdorf K., Poitou C., Puder L., Swain J., Stewart M., Yuan G., Wabitsch M., Kühnen P., Pigeon-Kherchiche P., Flaus-Furmaniuk A., Bald M., Denzer C., von Schnurbein J., Abawi O., Blume-Peytavi U., Krabusch P., Mai K., Schnabel D., Wiegand S., Flück C.E., Schulz E., Voss E., Bratina N., Weiss K., Martos-Moreno G.Á., Danset A., Gougis P., Dubern B., van den Akker E.L., Bahm A.L., Connors H.S., Farooqi I.S., Gordon G.A., Swain J.M., Stewart M.W., Yuan G. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8:960–970. doi: 10.1016/S2213-8587(20)30364-8. - DOI - PubMed
    1. Lee A.C.-L., Harris J.L., Khanna K.K., Hong J.-H. A comprehensive review on current advances in peptide drug development and design. Int J Mol Sci. 2019;20 doi: 10.3390/ijms20102383. - DOI - PMC - PubMed
    1. Ladner R.C., Sato A.K., Gorzelany J., de Souza M. Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov Today. 2004;9:525–529. doi: 10.1016/S1359-6446(04)03104-6. - DOI - PubMed